USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME FOR TREATING BREAST CANCER
A use of mitoxantrone hydrochloride liposome as a unique active ingredient for preparing drugs for treating breast cancer. The Breast cancer is preferably advanced breast cancer. Moreover, also provided is a method for treating the breast cancer. The method is to administer mitoxantrone hydrochloride liposome in a therapeutic effective amount to breast cancer patients, and the therapeutic effective amount means 8-30 mg/m<sup>2</sup>, according to mitoxantrone. Clinical trial results show that the mitoxantrone hydrochloride liposome has better efficacy and fewer adverse reactions, and especially significantly reduced cardiotoxicity, compared with a common mitoxantrone hydrochloride injection..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 14. Feb. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LI CHUNLEI [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-02-14, Last update posted on www.tib.eu: 2024-02-27, Last updated: 2024-03-01 |
|---|
| Patentnummer: |
EP4098251 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA016555023 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA016555023 | ||
| 003 | DE-627 | ||
| 005 | 20240301101105.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230607s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA016555023 | ||
| 035 | |a (EPA)EP4098251 | ||
| 035 | |a (EPA)77292048 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LI CHUNLEI |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME FOR TREATING BREAST CANCER |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-02-14, Last update posted on www.tib.eu: 2024-02-27, Last updated: 2024-03-01 | ||
| 520 | |a A use of mitoxantrone hydrochloride liposome as a unique active ingredient for preparing drugs for treating breast cancer. The Breast cancer is preferably advanced breast cancer. Moreover, also provided is a method for treating the breast cancer. The method is to administer mitoxantrone hydrochloride liposome in a therapeutic effective amount to breast cancer patients, and the therapeutic effective amount means 8-30 mg/m<sup>2</sup>, according to mitoxantrone. Clinical trial results show that the mitoxantrone hydrochloride liposome has better efficacy and fewer adverse reactions, and especially significantly reduced cardiotoxicity, compared with a common mitoxantrone hydrochloride injection. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a WANG XIAODONG |4 aut | |
| 700 | 0 | |a YANG XIUGAO |4 aut | |
| 700 | 0 | |a WANG LINGLING |4 aut | |
| 700 | 0 | |a DU YANLING |4 aut | |
| 700 | 0 | |a JIN QIUSHUANG |4 aut | |
| 700 | 0 | |a WANG SHIXIA |4 aut | |
| 700 | 0 | |a WANG XIAOLI |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 14. Feb. |
| 773 | 1 | 8 | |g year:2024 |g day:14 |g month:02 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/77292048/publication/EP4098251A1?q=EP4098251 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 14 |c 02 | ||